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Abstract 
Schizophrenia is a severe psychiatric disorder with no clear cause. Recent 
evidence suggests that N-methyl-D-aspartate (NMDA) receptor hypofunction may 
underlie the pathogenesis of schizophrenia. The posterior cingulate cortex (PCC) has 
been shown to be the most susceptible brain region to damage caused by NMDA 
hypofunction in rodents. This suggests that the PCC may play an important role in 
schizophrenia pathology. However, studies examining neurotransmitter balance in the 
PCC in schizophrenia have until now been neglected. Furthermore, the long-term 
consequences of NMDA hypofunction on neurotransmitter balance in animal models 
have not been studied. The aims of this study were to investigate neurotransmitter 
receptor binding profiles in the PCC in schizophrenia, while also examining the effects 
of chronic phencyclidine (PCP; an NMDA antagonist) treatment on neurotransmitter 
receptor binding in mouse brain in the long-term following treatment. To achieve these 
aims, the study was divided into two parts. 
In experimental part A, PCC sections from 10 schizophrenia and 11 control 
subjects matched for age, gender and post-mortem interval were obtained from the 
Tissue Resource Center, Sydney. Using quantitative autoradiography, the density of 
several neurotransmitter receptors was examined. The results demonstrated specific 
alterations in neurotransmitter receptors in the PCC in schizophrenia. Specifically, 
increased NMDA, gamma-aminobutyric acid A (GABAA) and cannabinoid 1 (CB1) 
receptor density was found in this region, along with reduced muscarinic 1/4 (M1/4) and 
serotonin 2A (5-hydroxy-tryptamine, 5HT2A) receptor density. No changes were found 
in α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA), kainate or M2/4 
receptor density in the PCC in schizophrenia subjects compared to controls. These 
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results have shown for the first time that there are specific neurotransmitter imbalances 
in this region, and it is possible that these changes stem from NMDA hypofunction. 
In experimental part B, mice were treated chronically (14 days) with PCP. Using 
quantitative autoradiography the density of several receptors was examined in the short 
(1hr and 24hr) and long-term (14 days) following chronic PCP treatment. In addition, 
clozapine and haloperidol were tested for their ability to prevent the PCP-induced 
alterations in neurotransmitter receptor density. The results showed opposing effects of 
PCP treatment on neurotransmitter receptor density in the short compared to the long-
term. While there were limited increases in NMDA receptor density in the short-term, 
there were widespread reductions in NMDA receptor density in the long-term following 
chronic PCP treatment. Muscarinic M1/4 receptor binding, which was increased in the 
short-term, showed reductions in the long-term in the limbic system, caudate-putamen 
and cortex, but not in the thalamus in which no change was found. Clozapine and 
haloperidol treatments were both unable to prevent the PCP-induced long-term changes 
in receptor density. 
In conclusion, this study has provided new information regarding 
neurotransmitter alterations in the PCC in schizophrenia and in mouse brain in the long-
term following chronic PCP treatment. These findings may assist not only in 
understanding the pathology of schizophrenia, but also for designing new 
pharmacological treatments for this disease. 
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List of Abbreviations 




Acb  Nucleus accumbens 
ACC Anterior cingulate cortex 
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid 
APD Antipsychotic drug 
BSA Bovine serum albumin 
CNS Central nervous system 
CPu Caudate-putamen 
D-AP5 D-2-amino-5-phosphnopentanoate 
DSM Diagnostic and Statistical Manual of Mental Disorders 
EDTA Ethylenediamine teraacetic acid 
GABA Gamma-aminobutyric acid 
GAD Glutamic acid decarboxylase 
GAT 1 GABA transporter 1 
HEPES N-(2-Hydroxyethyl) piperazine-N`-2-ethane sulfonic acid 
LSD Lysergic acid diethylamide 
LV Lateroventral 
MRI Magnetic resonance imaging 
NHMRC National Health and Medical Research Council 
NMDA N-methyl-D-aspartate 
PCC Posterior cingulate cortex 
PCP  Phencyclidine 
PET Positron emission tomography 
RSC Retrosplenial cortex 
Δ9-THC Δ9-tetrahydrocannabinol 
 
 
 
 
 
 
 
 
 
 
 
 
 
